Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Le Naour

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Oncoimmunology|March 6, 2023
Trial watch: Toll-like receptor ligands in cancer therapyJulie Le Naour, Guido Kroemer
Oncoimmunology|May 12, 2020
The ambiguous role of FPR1 in immunity and inflammationErika Vacchelli, Julie Le Naour, Guido Kroemer
Oncoimmunology|May 5, 2020
FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatinJonathan G Pol, Julie Le Naour, Guido Kroemer
Oncoimmunology|September 16, 2020
Trial watch: TLR3 agonists in cancer therapyJulie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Oncoimmunology|September 16, 2020
Trial watch: IDO inhibitors in cancer therapyJulie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Oncoimmunology|September 16, 2020
Trial watch: STING agonists in cancer therapyJulie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, et al.
Oncoimmunology|October 22, 2021
Trial watch: intratumoral immunotherapyJuliette Humeau, Julie Le Naour, Lorenzo Galluzzi, et al.
Oncoimmunology|September 16, 2020
Trial Watch: experimental TLR7/TLR8 agonists for oncological indicationsGiorgio Frega, Qi Wu, Julie Le Naour, et al.
Oncoimmunology|March 27, 2023
Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancerVincent Carbonnier, Julie Le Naour, Thomas Bachelot, et al.
Oncoimmunology|January 25, 2021
A major genetic accelerator of cancer diagnosis: rs867228 in FPR1Zsofia Sztupinszki, Julie Le Naour, Erika Vacchelli, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Oncoimmunology|March 6, 2023
Trial watch: Toll-like receptor ligands in cancer therapyJulie Le Naour, Guido Kroemer
Oncoimmunology|May 12, 2020
The ambiguous role of FPR1 in immunity and inflammationErika Vacchelli, Julie Le Naour, Guido Kroemer
Oncoimmunology|May 5, 2020
FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatinJonathan G Pol, Julie Le Naour, Guido Kroemer
Oncoimmunology|September 16, 2020
Trial watch: TLR3 agonists in cancer therapyJulie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Oncoimmunology|September 16, 2020
Trial watch: IDO inhibitors in cancer therapyJulie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Oncoimmunology|September 16, 2020
Trial watch: STING agonists in cancer therapyJulie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, et al.
Oncoimmunology|October 22, 2021
Trial watch: intratumoral immunotherapyJuliette Humeau, Julie Le Naour, Lorenzo Galluzzi, et al.
Oncoimmunology|September 16, 2020
Trial Watch: experimental TLR7/TLR8 agonists for oncological indicationsGiorgio Frega, Qi Wu, Julie Le Naour, et al.
Oncoimmunology|March 27, 2023
Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancerVincent Carbonnier, Julie Le Naour, Thomas Bachelot, et al.
Oncoimmunology|January 25, 2021
A major genetic accelerator of cancer diagnosis: rs867228 in FPR1Zsofia Sztupinszki, Julie Le Naour, Erika Vacchelli, et al.
Pageof 3